US 6,680,203 B2Granted

Fourier transform mass spectrometry of complex biological samples

AssigneeEsperion Therapeutics, Inc.

InventorsJean-Louis H. Dasseux, Roger S. Newton, Thomas J. Rea, Charles L. Bisgaier, Michael E. Pape

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present invention relates to methods for high information content (HIC) analysis or screening of complex biological systems using Fourier transform mass spectrometry (FTMS). The present methods are useful for analyzing complex biological mixtures containing both high molecular weight molecules (e.g., polynucleotides, proteins, polysaccharides) and low molecular weight molecules (e.g., oligonucleotides, peptides, lipids, oligosaccharides, steroid hormones, catabolic and metabolic intermediates) permit the elucidation of molecular differences between complex biological samples, and permit the identification of biologically active molecules (e.g. therapeutically active drugs, etc.).

Claims32

Dependent claims

A method for identifying one or more endogenous molecules that differ in abundance between a first cell population and a second cell population, comprising:

(a) comparing a first Fourier Transform Mass Spectrometry (FTMS) peak profile obtained from the first cell population with a second FTMS peak profile obtained from the second cell population;
(b) identifying one or more peaks that differ in intensity in the first FTMS peak profile relative to the second FTMS peak profile, which one or more peaks correspond to one or more molecules that differ in abundance between a first cell population and a second cell population;
and
(c) identifying said one or more said endogenals molecules that differ in abundance between a first cell population and a second cell population either directly from mass-to-charge (m/z) ratio or through additional fragmentation of said one or more molecules.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 09/735,707Filed 12 Dec 2000 · us provisional application
Priority: 10 Jul 2000
Published: US 2002/0019023 A114 Feb 2002
Granted: 20 Jan 2004
Term ends: Not estimatedThe source records don’t support an estimate.

Classification10 codes

G01N 33/5011
For testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics: for testing antineoplastic activity
G01N 33/5008
Involving human or animal cells: for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
G01N 33/502
For testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics: for testing non-proliferative effects
G01N 33/5038
For testing non-proliferative effects: involving detection of metabolites per se